IKBKE (NM_014002) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC212481L4V
- LentiORF®
-
Lenti ORF particles, IKBKE (mGFP-tagged) - Human inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE), transcript variant 1, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 9,975.00
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | IKBKE (NM_014002) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | IKK-E; IKK-i; IKKE; IKKI |
Vector | pLenti-C-mGFP-P2A-Puro |
ACCN | NM_014002 |
ORF Size | 2148 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC212481).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_014002.2 |
RefSeq Size | 3263 bp |
RefSeq ORF | 2151 bp |
Locus ID | 9641 |
Domains | pkinase |
Protein Families | Druggable Genome, Protein Kinase |
Protein Pathways | Cytosolic DNA-sensing pathway, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway |
MW | 80.3 kDa |
Gene Summary | IKBKE is a noncanonical I-kappa-B (see MIM 164008) kinase (IKK) that is essential for regulating antiviral signaling pathways. IKBKE has also been identified as a breast cancer (MIM 114480) oncogene and is amplified and overexpressed in over 30% of breast carcinomas and breast cancer cell lines (Hutti et al., 2009 [PubMed 19481526]).[supplied by OMIM, Oct 2009] |
Documents
Product Manuals |
FAQs |
SDS |